MFM Clinical Protocol — Provider Education

Postpartum Furosemide
(Lasix) Protocol

Accelerated blood pressure recovery in hypertensive disorders of pregnancy

Postpartum Hypertension Preeclampsia Furosemide Provider Education

Based on: Lopes Perdigao et al., Hypertension 2021;77:1517–1524
Greater Atlanta Women’s Healthcare OB Call Group • Protocol Effective March 2026

The Problem

Postpartum Hypertension: A Leading Cause of Readmission

Blood pressure rises days 3–6 postpartum as fluid mobilizes from the interstitium back into the intravascular compartment

18%
of maternal deaths worldwide attributable to hypertensive disorders of pregnancy
27%
of postpartum readmissions caused by persistent hypertension
Days
3–6
peak BP rise from postpartum fluid mobilization
💡

BP initially decreases in the first 48 hours after delivery, then rises as sodium mobilizes into the vascular space — creating a critical window for diuretic intervention.

WHO, 2006 • ACOG Practice Bulletin, 2020 • Hirshberg et al., J Perinatol 2016
The Evidence

Randomized, Double-Blind, Placebo-Controlled Trial

Lopes Perdigao et al., Hypertension 2021 • University of Pennsylvania

384 Women with HDP Randomized, Double-Blind Furosemide Group n = 192 20 mg PO daily × 5 days Placebo Group n = 192 Identical placebo tablet 5% Persistent HTN at Day 7 Median 8.5 days to resolution 16% Persistent HTN at Day 7 Median 10.5 days to resolution
Lopes Perdigao et al., Hypertension 2021 • n=384 • Primary outcome: persistent hypertension at 7 days postpartum
Study Results

BP Trajectories by Treatment Group

Non-Severe HDP — Postpartum Systolic BP Over Time (p < 0.0001)

140 165 155 145 140 130 120 0 1 2 3 5 7 10 14 Days Postpartum Furosemide Placebo ‒‒ HTN threshold (140 mmHg)
Adapted from Lopes Perdigao et al., Hypertension 2021, Figure 2 • Non-severe HDP subgroup • Systolic BP trajectories, approximate representation
Clinical Impact

Clinical Implications

Furosemide Significantly Reduces Persistent Postpartum Hypertension — Non-Severe HDP Subgroup

NNT
= 13
women treated to prevent 1 case of persistent HTN at day 7
60%
reduction in elevated BPs at 7 days postpartum (aRR 0.26)
2 d
faster resolution of hypertension (8.5 vs 10.5 days)
No
increase in severe maternal morbidity or adverse events
⚠️

Effect most prominent in non-severe HDP — aRR 0.26 (95% CI 0.10–0.67) • aHR 1.62 (95% CI 1.22–2.15) for time to BP resolution. Effect attenuated in severe HDP subgroup.

Lopes Perdigao et al., Hypertension 2021 • Table 2 • Adjusted for mode of delivery and antihypertensive use
Primary Endpoints

Key Outcomes — Non-Severe HDP

Primary endpoints adjusted for mode of delivery

Furosemide
5%
Persistent HTN at 7 days postpartum
Placebo
16%
Persistent HTN at 7 days postpartum
Furosemide
8.5 d
Median days to BP resolution (<140/90)
Placebo
10.5 d
Median days to BP resolution (<140/90)

aRR 0.26 (95% CI 0.10–0.67)
aHR 1.62 (95% CI 1.22–2.15)

No difference in readmission rates, potassium levels, or severe maternal morbidity between groups

Lopes Perdigao et al., Hypertension 2021 • Table 2
Call Group Protocol

The Postpartum Lasix Protocol

Greater Atlanta Women’s Healthcare OB Call Group — Effective March 2026

Gestational Hypertension Preeclampsia (w/ or w/o severe features) Chronic HTN with Superimposed Preeclampsia
Medication Dose Route Duration
Furosemide (Lasix) 20 mg PO once daily 5 days
Potassium Chloride (K-Dur) 20 mEq PO once daily 5 days
Greater Atlanta Women’s Healthcare OB Call Group Protocol, March 17, 2026 • Based on Lopes Perdigao et al., Hypertension 2021
Implementation

Order Entry & Safety Checklist

📱

HeartSafe Motherhood — text-based BP surveillance program. Enroll all patients with HDP prior to discharge to capture late postpartum hypertension.

⚠️

Call Protocol — For BP ≥ 160/110 at any point, initiate severe-range hypertension management per ACOG Practice Bulletin. Do not delay for oral medications.

Greater Atlanta Women’s Healthcare OB Call Group Protocol, 2026 • Lopes Perdigao et al., 2021 • ACOG Practice Bulletin, 2020
← OpenMFM Library